New biomarker to determine whether immunotherapy may work in people with colon and rectal cancer

14/04/2026

At present, only around 5% of patients with colon cancer are candidates for immunotherapy. This new biomarker could make it possible to determine more accurately which individuals may receive this treatment with a likelihood of success and expand the number of patients who could benefit from it. The study, led by the Hospital del Mar Research Institute and IRB Barcelona, shows that the determination of this protein, CTHRC1, can be used to assess patient prognosis. At the same time, it opens up new avenues to approach this type of tumour. The research team has demonstrated that this biomarker can be detected using routine diagnostic tests in the clinical practice of any Pathology service.

Read more sobre "New biomarker to determine whether immunotherapy may work in people with colon and rectal cancer"